Genital Herpes

The honest answer: you often can't know without testing. About 80% of people with herpes have no symptoms they recognize as herpes: outbreaks may be subtle (a small fissure, mild irritation, a sore that comes and goes) or entirely absent. If you have a visible sore or blistering in the genital area, the most reliable approach is to get a PCR swab of that lesion immediately, this can confirm or rule out herpes and type it as HSV-1 or HSV-2. If you have no current symptoms but want to know your baseline status, a blood IgG test can detect past exposure: but be aware it takes at least 12–16 weeks after exposure to be reliably positive, and low-positive results can be false positives. Testing with context, knowing when your potential exposure was and what symptoms if any you've had, gives you the most meaningful result.

A classic herpes outbreak starts with tingling, burning, or itching at the site, the prodrome, followed by the appearance of small red bumps that rapidly form fluid-filled blisters, which then rupture into shallow, painful open sores (ulcers), crust over, and heal without scarring. In the genital area, this can involve the labia, penis, scrotum, perineum, buttocks, inner thighs, or anus. The first (primary) outbreak is usually the most severe and may include dozens of lesions alongside flu-like symptoms. Recurrent outbreaks are typically much milder: sometimes just one or two small sores, lasting 3–7 days. But many outbreaks are far subtler than the textbook description: a single small fissure near the vaginal opening, a tiny sore on the scrotum, or brief redness that resolves in a few days without ever being swabbed. This is one reason herpes is so often missed or misattributed: it doesn't always look dramatic, and it is easily confused with other conditions like yeast infections, ingrown hairs, or razor irritation.

Yes, and this is the most consequential fact about herpes transmission. HSV sheds from the skin surface even between outbreaks, with no visible sores, no symptoms, and no way for you or your partner to detect it. Studies using daily PCR swabs show that HSV-2 sheds on approximately 10–30% of days in untreated individuals. Most herpes transmission, roughly 70% of it, according to transmission studies, happens during these asymptomatic periods, not during visible outbreaks (when most people avoid sex anyway). Suppressive antiviral therapy cuts shedding frequency by approximately half and should be considered by anyone concerned about protecting a partner. Condoms also reduce but don't eliminate risk. There is no way to know with certainty whether shedding is occurring on any given day without active PCR swab testing of the genital skin, which is not practical in daily life.

Both herpes simplex viruses cause the same type of infection, blisters and sores, and both can infect the mouth or genitals. HSV-1 was historically 'the oral herpes virus' (responsible for cold sores on the lips) and HSV-2 'the genital herpes virus,' but that distinction has broken down significantly. HSV-1 now causes a meaningful and growing proportion of genital herpes cases, predominantly through oral-to-genital transmission. From a clinical standpoint there are some important differences: genital HSV-1 tends to have fewer recurrences (typically 0–1 per year vs. 4–5 per year for HSV-2) and lower asymptomatic shedding rates, which is relevant for transmission risk discussions. A blood test that comes back positive for HSV-1 cannot tell you where you carry the infection: most HSV-1-positive adults have oral herpes, not genital, and a positive blood test alone is not a genital herpes diagnosis. Getting the virus typed (HSV-1 vs. HSV-2) from a lesion swab is clinically useful for prognosis and informing conversations with partners.

Yes, and this route is increasingly common. If someone with oral HSV-1 (cold sores) performs oral sex on a partner, they can transmit the virus to that partner's genitals. The resulting genital infection is caused by HSV-1 rather than HSV-2: and is clinically real genital herpes in terms of symptoms and transmission potential, though recurrences are usually less frequent. This dynamic is a significant driver of new genital herpes cases in younger adults: a generation that grew up with lower rates of childhood oral HSV-1 infection (less transmission in early childhood) has less pre-existing immunity to HSV-1, making genital acquisition through oral sex more likely. If a partner has active cold sores, avoiding oral sex until the sore has fully healed is the most effective precaution, that is the highest-risk window for oral-to-genital transmission. Dental dams and condoms can also reduce (though not eliminate) risk.

There's no single script, but some principles consistently help. Choose a calm, private moment, not during or immediately before sex. Lead with the facts (what herpes is, how common it is, how manageable it is) rather than with shame or apology. Share what you're doing to reduce transmission risk: suppressive therapy, condom use, avoiding sex during outbreaks. Give your partner time to process and ask questions, they may need time and information before responding. Research on partner disclosure consistently shows that the feared worst-case reaction is much less common than people expect; most partners of people with herpes choose to continue the relationship after disclosure, especially when the person disclosing is calm and well-informed. Many people find it helpful to share a reliable factsheet or prepare with a counselor, particularly early after a diagnosis when the emotional weight is heaviest. In most U.S. states, disclosing to sexual partners before sex is both a legal and ethical obligation.

Not necessarily at the same frequency, outbreaks typically become less frequent over time. In the first year after primary HSV-2 infection, most people average 4–5 recurrences. Over years, frequency tends to decline for many individuals, though the pattern varies widely. Some people have frequent recurrences indefinitely; others have only a few and then years of silence. Daily suppressive antiviral therapy (valacyclovir 500mg or 1g, acyclovir 400mg twice daily) reduces outbreak frequency by 70–80% and is a strong option for anyone with 6 or more outbreaks per year, or who finds outbreaks significantly affecting their quality of life. Genital HSV-1 recurs much less frequently, typically 0–1 times per year, which is clinically meaningful if your infection was typed at diagnosis.

No, not currently. Once HSV establishes latency in sensory nerve ganglia, no existing therapy can eradicate it. Antiviral drugs suppress viral replication but don't touch latent virus in nerve cells. That said, 'no cure' does not mean 'no treatment': the available antivirals (acyclovir, valacyclovir, famciclovir) are highly effective at reducing outbreaks, cutting asymptomatic shedding, and lowering partner transmission risk. Herpes vaccine research has been ongoing for decades, with several candidates in trials including mRNA-based approaches similar to COVID-19 vaccine platforms. A therapeutic vaccine (designed to reduce outbreaks in people who already have herpes) and a prophylactic vaccine (to prevent acquisition) are both being studied actively. No vaccine has reached regulatory approval as of mid-2026, but the field is more active than at any prior point, making a functional preventive or therapeutic vaccine a realistic medium-term possibility.

Yes. This is the core mechanism behind herpes's prevalence. Asymptomatic viral shedding, the release of infectious HSV from skin between outbreaks, occurs on roughly 10–30% of days for HSV-2. Most people who transmit herpes don't have a visible sore at the time; they have no symptoms at all. A partner can honestly tell you they have no current outbreak and be telling the complete truth, while still being potentially contagious on that day. This is not deception, it's the biology of herpes. The combination of suppressive antivirals, consistent condoms, and avoiding sex when symptoms suggest an outbreak or prodrome brings the annual transmission risk down to approximately 1–2% per year for a sero-discordant couple, a level that many couples find acceptable and manageable.

Not yet, no herpes vaccine has been approved by the FDA as of 2026. Developing one has proven scientifically challenging: prior vaccine candidates that showed strong preclinical results failed in large-scale human trials. However, the landscape has changed meaningfully in recent years. Several new approaches are in clinical trials, including mRNA-based vaccines leveraging the platform that produced COVID-19 vaccines, replication-defective HSV constructs, and therapeutic vaccines aimed at reducing outbreaks in people already infected. A herpes vaccine remains a realistic future possibility but no reliable timeline for approval exists. People managing herpes today should plan around current evidence-based tools, antivirals, condoms, and transparent communication with partners, rather than waiting for a vaccine that has no confirmed arrival date.

Herpes does not cause miscarriage, birth defects, or problems during the pregnancy itself in the vast majority of cases. The concern is neonatal herpes, transmission to the baby during delivery, which is rare but potentially serious. The risk depends critically on timing: if a person acquires primary HSV infection in the last trimester (especially the last four weeks), transmission risk at delivery is approximately 40–50%, because they haven't yet developed antibodies to pass to the fetus. For people with established recurrent herpes, the transmission risk at delivery is less than 3%. Standard risk-reduction strategies include: disclosing herpes history to your OB at the first prenatal visit; taking suppressive valacyclovir starting at 36 weeks to reduce shedding at delivery; and having a cesarean section if genital lesions or prodromal symptoms are present when labor begins. With these measures in place, the vast majority of people with herpes deliver healthy babies, herpes is not a contraindication to pregnancy.

Yes, substantially. Genital herpes increases HIV acquisition risk by approximately 2–4 fold per sexual act in settings where HIV is circulating. The mechanism is direct: genital ulcers created by HSV break down the mucosal barrier that normally blocks HIV entry, and the inflamed tissue at the ulcer site is densely populated with CD4+ T cells and dendritic cells, exactly the cells HIV preferentially infects. Even between outbreaks, subclinical inflammation from HSV may elevate susceptibility. For people on PrEP or in high-HIV-prevalence settings, controlling HSV with suppressive therapy is clinically relevant and worth discussing with a provider. Conversely, for people living with HIV, HSV reactivation can increase HIV viral load in genital secretions, potentially elevating transmission risk to partners. The HSV-HIV interaction is one reason STI management is considered integral to HIV prevention, not separate from it.

Herpes outbreaks occur when latent HSV in the sensory ganglia reactivates and travels down the nerve to the skin. The triggers that prompt reactivation are not fully understood, but several are well-established: psychological stress (one of the strongest and most consistently reported triggers); physical illness, particularly febrile illness; UV sun exposure to the affected area; hormonal fluctuations including menstrual cycles; local genital trauma from friction, injury, or procedures; immunosuppression from any cause; and friction or irritation from tight clothing. Many people identify their personal pattern over time and can take episodic antivirals at the first prodromal sign to abort or shorten an outbreak. Others, particularly those with frequent stress-triggered recurrences, find daily suppressive therapy more practical than trying to predict episodes. There's no way to guarantee zero outbreaks, but many people go years between recurrences.